Noah Rosenberg Purchases 4,200 Shares of Verrica Pharmaceuticals (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CMO Noah Rosenberg bought 4,200 shares of the company’s stock in a transaction on Monday, August 17th. The shares were acquired at an average price of $4.91 per share, for a total transaction of $20,622.00. Following the transaction, the chief marketing officer directly owned 6,557 shares in the company, valued at $32,194.87. This trade represents a 178.19% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA stock traded down $0.21 during trading hours on Tuesday, reaching $4.68. 46,708 shares of the company’s stock were exchanged, compared to its average volume of 92,498. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.45 and a quick ratio of 1.33. The company’s 50 day moving average is $5.68 and its two-hundred day moving average is $5.93. The company has a market cap of $80.40 million, a P/E ratio of -2.80 and a beta of 1.49. Verrica Pharmaceuticals Inc. has a 1 year low of $3.28 and a 1 year high of $9.82.

Wall Street Analyst Weigh In

Several research firms have issued reports on VRCA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, HC Wainwright assumed coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target on the stock. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.50.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its stake in shares of Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after acquiring an additional 44,275 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in Verrica Pharmaceuticals in the 2nd quarter valued at approximately $28,000. Invesco Ltd. increased its stake in Verrica Pharmaceuticals by 64.8% in the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock valued at $33,000 after purchasing an additional 29,256 shares in the last quarter. Bridgeway Capital Management LLC acquired a new position in Verrica Pharmaceuticals during the third quarter worth $52,000. Finally, Goldman Sachs Group Inc. raised its holdings in Verrica Pharmaceuticals by 23.3% during the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock worth $61,000 after purchasing an additional 26,308 shares during the last quarter. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.